On January 25, 2022 Cure Genetics of Suzhou reported that closed a $60 million Series B round to advance clinical development of its cell therapy candidates for hematological and solid tumors (Press release, CureGenetics, JAN 25, 2022, View Source [SID1234607390]). Cure was established by CRISPR pioneers in 2016 to develop therapies for difficult-to-treat cancers and genetic diseases. Its CRISPR-mediated single or multiplex gene editing platform is aimed at producing more effective or safer cell therapy products, including universal CAR-T candidates. The financing round was led by Advantech Capital and joined by Oriza Holdings, Blue Ocean Private Equity and Qiming Venture Capital

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!